Corxel raises $287m as obesity continues to spark investor interest
Corxel Pharmaceuticals has raised $287m to fund its suite of cardiometabolic assets, signifying that investor appetite for weight loss drug…
Metabolic Disorders
-
-
Drugmakers welcome FDA’s GLP-1RA suicide warning removal request
The US Food and Drug Administration (FDA) has requested that pharma companies marketing glucagon-like peptide-1 receptor agonists (GLP-1RAs) no longer…
-
Eli Lilly signs $1.3bn obesity-focused research deal with Nimbus
Eli Lilly has signed a research and licence agreement with Nimbus Therapeutics, aiming to develop a new oral weight loss…
-
Novo beats Lilly to first FDA-approved GLP-1RA pill for obesity
Novo Nordisk has ushered in a new era of obesity treatment – gaining the first US Food and Drug Administration…
-
Pfizer gains another obesity asset with $2bn deal for YaoPharma’s GLP-1RA
Pfizer has confirmed another push into the obesity market in the form of a licencing deal worth up to approximately…
-
WHO backs use of GLP-1RAs for weight loss despite shortage warning
The World Health Organization (WHO) has endorsed the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) for the treatment of obesity,…
-
Eli Lilly flies the pharma flag in tech-heavy $1tn market cap club
Eli Lilly’s market capitalisation hit the $1tn mark in the past week, becoming the first healthcare company in the world…
-
Eli Lilly and Novo Nordisk disown Mangoceuticals’ GLP-1RA partnership claim
Eli Lilly and Novo Nordisk have rebutted claims that they have partnered with telehealth provider Mangoceuticals, sending the online company's…
-
Sandoz CEO forecasts a Q1 or Q2 market entry for semaglutide biosimilars in Canada
Sandoz CEO Richard Saynor predicts biosimilars referencing semaglutide to enter the Canadian market in early in 2026, as the patent…
-
Rhythm forced to wait for Imcivree expansion as FDA delays decision
The US Food and Drug Administration (FDA) has extended the review period for expanded approval of Rhythm Pharmaceuticals’ Imcivree (setmelanotide)…
